Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Urinary Bladder Neoplasms 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Camurati-Engelmann Syndrome 1Advanced Solid Tumors 1

Interventions

durvalumab 7Carboplatin 7Docetaxel 6Paclitaxel 5Nivolumab 5talazoparib 4linifanib 4Cisplatin 4trifluridine tipiracil drug combination 3tremelimumab 3tislelizumab 3depatuxizumab 3ST 1481 3S 1 (combination) 3Panobinostat 3Gemcitabine 3zimberelimab 2toripalimab 2olaparib 2motesanib diphosphate 2mogamulizumab 2TAS-114 2Sorafenib 2Rifampin 2PM 01183 2Oxaliplatin 2MLN 8237 2Itraconazole 2Injections 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Solid Tumors × ascrinvacumab × Clear all
NCT00557856 2015-10-19

A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors

Pfizer

Phase 1 Completed
70 enrolled 22 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡